Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on our Manocept platform to enhance patient care by identifying the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and targeted treatment.
Company profile
Ticker
NAVB
Exchange
Website
CEO
Jed Latkin
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
NEOPROBE CORP
SEC CIK
Corporate docs
Subsidiaries
Navidea Biopharmaceuticals Europe Limited • Navidea Biopharmaceuticals Limited • Macrophage Therapeutics, Inc. ...
IRS number
311080091
NAVB stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
1 Feb 24
EFFECT
Notice of effectiveness
1 Feb 24
EFFECT
Notice of effectiveness
1 Feb 24
EFFECT
Notice of effectiveness
1 Feb 24
EFFECT
Notice of effectiveness
1 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Jan 24
POS AM
Prospectus update (post-effective amendment)
26 Jan 24
Transcripts
NAVB
Earnings call transcript
2022 Q4
22 Mar 23
NAVB
Earnings call transcript
2022 Q3
16 Nov 22
NAVB
Earnings call transcript
2022 Q2
9 Sep 22
NAVB
Earnings call transcript
2022 Q1
13 May 22
NAVB
Earnings call transcript
2021 Q4
24 Mar 22
NAVB
Earnings call transcript
2021 Q3
11 Nov 21
NAVB
Earnings call transcript
2021 Q2
12 Aug 21
NAVB
Earnings call transcript
2021 Q1
12 May 21
NAVB
Earnings call transcript
2020 Q4
25 Mar 21
NAVB
Earnings call transcript
2020 Q3
12 Nov 20
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 3.86 mm | 3.86 mm | 3.86 mm | 3.86 mm | 3.86 mm | 3.86 mm |
Cash burn (monthly) | 759.68 k | 61.33 k | 751.78 k | 882.34 k | 3.42 mm | 809.48 k |
Cash used (since last report) | 5.23 mm | 422.21 k | 5.18 mm | 6.07 mm | 23.52 mm | 5.57 mm |
Cash remaining | -1.36 mm | 3.44 mm | -1.31 mm | -2.21 mm | -19.65 mm | -1.71 mm |
Runway (months of cash) | -1.8 | 56.1 | -1.7 | -2.5 | -5.8 | -2.1 |
Institutional ownership, Q3 2023
2.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 23 |
Opened positions | 5 |
Closed positions | 3 |
Increased positions | 5 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 195.84 mm |
Total shares | 2.52 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Allred Capital Management | 466.69 k | $41.86 mm |
STT State Street | 412.74 k | $37.02 mm |
Geode Capital Management | 368.83 k | $33.08 mm |
VIRT Virtu Financial | 333.07 k | $30.00 k |
Vanguard | 276.49 k | $24.80 mm |
Warberg Asset Management | 195.00 k | $17.49 mm |
UBS UBS Group AG - Registered Shares | 149.61 k | $13.47 mm |
BLK Blackrock | 113.03 k | $10.14 mm |
Level Four Advisory Services | 55.56 k | $4.98 mm |
Boothbay Fund Management | 40.00 k | $3.59 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
27 Nov 23 | Scott John K Jr. | Series G Redeemable Preferred Stock | Other | Dispose J | No | No | 0 | 2,270 | 0.00 | 0 |
27 Nov 23 | Scott John K Jr. | Series J Convertible Preffered Stock Common Stock | Other | Acquire J | No | No | 100 | 64,289 | 6.43 mm | 64,289 |
27 Nov 23 | Scott John K Jr. | Series I Convertible Preferred Stock Common Stock | Other | Dispose J | No | No | 1000 | 2,400 | 2.40 mm | 0 |
16 Nov 23 | Jill Stefanelli | Common Stock | Grant | Acquire A | No | No | 0 | 416,667 | 0.00 | 941,667 |
16 Nov 23 | Jill Stefanelli | Common Stock | Grant | Acquire A | No | No | 0 | 275,000 | 0.00 | 525,000 |
16 Nov 23 | Dana J Moss | Common Stock | Grant | Acquire A | No | No | 0 | 416,667 | 0.00 | 866,667 |
16 Nov 23 | Dana J Moss | Common Stock | Grant | Acquire A | No | No | 0 | 200,000 | 0.00 | 450,000 |
10 Nov 23 | Craig Dais | Common Stock | Grant | Acquire A | No | No | 0 | 973,633 | 0.00 | 973,633 |